AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2019 - ResearchAndMarkets.com

April 16, 2019

DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 2, 43, 29, 1, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 2 and 1 molecules, respectively.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
  3. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
  4. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
  5. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
  6. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
  7. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
  8. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
  9. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
  10. Appendix

Companies Mentioned

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Aduro BioTech Inc
  • Affimed GmbH
  • AlfaSigma SpA
  • Alissa Pharma
  • Anhui Anke Biotechnology (Group) Co Ltd
  • Apollomics Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • BeiGene Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • Bristol-Myers Squibb Co
  • Carrick Therapeutics Ltd
  • Celgene Corp
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellectis SA
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • Checkpoint Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Constellation Pharmaceuticals Inc
  • Curis Inc
  • Eureka Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • FLX Bio Inc
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Immunomedics Inc
  • Incyte Corp
  • Inhibrx LP
  • Jiangsu Hengrui Medicine Co Ltd
  • Kiromic Inc
  • Kite Pharma Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Molecular Templates Inc
  • NantKwest Inc
  • NBE-Therapeutics AG
  • Recursion Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5e6axt

View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005668/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Lymphoma Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/16/2019 09:40 AM/DISC: 04/16/2019 09:40 AM

http://www.businesswire.com/news/home/20190416005668/en